Canadian Based Peptide Supplier|Ships from British Columbia, Canada|International Shipping Available|HPLC-Tested Batches|>99% Purity Specification|Same Day Shipping|Batch-Specific COAs|Canadian Based Peptide Supplier|Ships from British Columbia, Canada|International Shipping Available|HPLC-Tested Batches|>99% Purity Specification|Same Day Shipping|Batch-Specific COAs|Canadian Based Peptide Supplier|Ships from British Columbia, Canada|International Shipping Available|HPLC-Tested Batches|>99% Purity Specification|Same Day Shipping|Batch-Specific COAs|Canadian Based Peptide Supplier|Ships from British Columbia, Canada|International Shipping Available|HPLC-Tested Batches|>99% Purity Specification|Same Day Shipping|Batch-Specific COAs|
Science

Classes and Applications of Cell-Penetrating Peptides

Cell-penetrating peptides fall into categories like cationic, amphiphilic, and hydrophobic based on properties, with cationic and amphiphilic types making up 85%. Examples include TAT and Penetratin for cationic ones. These peptides aid tumor treatment, siRNA delivery, and inflammation therapy through specific mechanisms and studies.

Marcus Hopkin, PhD, Director of Research and Development at Volta Peptides.

Reviewed by Marcus Hopkin, PhD

Director of Research and Development, Volta Peptides

Written by Volta Peptides Editorial Team · Reviewed September 15, 2026

May 14, 2026Updated June 19, 20263 min read

Key Takeaways

  • •Cell-penetrating peptides, known as CPPs, come in various types.
  • •According to physical and chemical traits, CPPs split into three groups: cationic, amphiphilic, and hydrophobic.
  • •Cationic CPPs consist of short sequences high in arginine, lysine, and histidine.

Classes and Applications of Cell-Penetrating Peptides

Cell-penetrating peptides, known as CPPs, come in various types. Experts classify them by physicochemical properties, sources, intake mechanisms, and biomedical uses. No single standard exists for this grouping.

According to physical and chemical traits, CPPs split into three groups: cationic, amphiphilic, and hydrophobic. Cationic and amphiphilic forms lead, representing about 85% of cases. Hydrophobic types account for just 15%.

Cationic Cell-Penetrating Peptides

Cationic CPPs consist of short sequences high in arginine, lysine, and histidine. Known examples are TAT, Penetratin, Polyarginine, P22N, DPV3, and DPV6.

Arginine features a guanidine group that forms hydrogen bonds with negatively charged phosphate groups on cell membranes. This interaction aids entry at physiological pH. Research on oligo-arginine chains from 3 R to 12 R found that penetration ability rises when arginine reaches at least 8 units. Capacity grows further as arginine count increases.

Lysine shares cationic nature with arginine but lacks guanidine. On its own, lysine shows lower transmembrane efficiency.

Amphiphilic and Hydrophobic Cell-Penetrating Peptides

Amphiphilic CPPs contain both hydrophilic and hydrophobic regions. Subgroups include primary amphiphilic, secondary α-helix amphiphilic, β-folded amphiphilic, and proline-enriched amphiphilic forms.

Hydrophobic CPPs rely solely on non-polar amino acid residues. Their net charge stays below 20% of the total amino acid sequence charge. Some include hydrophobic motifs or chemical groups key to membrane penetration.

These hydrophobic CPPs receive less attention but do occur. Instances are fibroblast growth factor (K-FGF) and fibroblast growth factor 12 (F-GF12), both from Kaposi's sarcoma.

In Stock

GHRP-6 5mg

5mg

$33.16 USD
In Stock

HCG 5,000iu

$44 USD
In Stock

Ipamorelin 5mg

Batch purity 99.5%
$36 USD

Tumor Treatment with Cell-Penetrating Peptides

CPPs deliver chemotherapeutic drugs or biologic agents into cells using their penetration power. They release payloads in the cytoplasm or at target sites to boost effects against tumor cells.

Dubikovskaya et al. attached the R8 peptide to paclitaxel (PTX), a common chemotherapy agent, via a biolysable disulfide linker. Inside cells, high glutathione levels break this bond. Tests in cell cultures and animal models showed CPP-paclitaxel outperforms paclitaxel alone. It works even in paclitaxel-resistant cells.

Delivery of Oligonucleotides and siRNA

Peptide, protein, and gene-based large molecules hold promise for disease treatment. Their size and poor lipid solubility block easy cell membrane crossing, limiting medical use.

Standard delivery options cover liposome methods, viral vectors, electroporation, and microinjection. Drawbacks include low efficiency, high cell toxicity, safety issues, and weak targeting.

Cell-penetrating peptides address these gaps with safer transport. Oligonucleotides and siRNA control protein activation and gene expression after transcription. They enable targeted gene therapy. siRNA acts via post-transcriptional gene silencing.

Li et al. developed sTOLP, a system with siRNAOA-R8 and TF-modified lipid nanoparticles (LNP). This uses cell-penetrating peptidyl-octadecarginine (OA-R8) and transferrin (Tf) for multifunctional delivery. In mice with HepG2 tumors, sTOLP-encapsulated siRNA cut tumor growth by 61.7%. It targeted hepatocytes and tumor cells without sparking immunogenicity or liver and kidney toxicity.

Inflammation-Targeted Therapy

Nuclear transcription factor kappaB (NF-κB) regulates genes in cells. In its resting state, the P50-P65 dimer binds an inhibitory protein.

Activation of NF-κB links to many inflammatory processes. Combining CPP (8K, octa-Lysine) with the NF-κB essential regulator binding domain (NBD) targets this pathway. Dave e

Research Use Only. This article is provided for informational and educational purposes only. The compounds and topics discussed are intended solely for laboratory and scientific research. This content does not constitute medical advice, and Volta Peptides does not endorse or promote human consumption of any research compound.

About the reviewer

Marcus Hopkin, PhD, Director of Research and Development at Volta Peptides.

Marcus Hopkin, PhD

Director of Research and Development, Volta Peptides

Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.

Marcus reviewed this article for scientific and analytical accuracy on September 15, 2026. He did not write it. Technical review is internal review and is not peer review, independent third-party review or medical review.

Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.

Shop Research Peptides

In Stock

GHRP-6 5mg

5mg

$33.16 USD
In Stock

HCG 5,000iu

$44 USD
In Stock

Ipamorelin 5mg

Batch purity 99.5%
$36 USD
In Stock

KPV 10mg

Batch purity 99.7%
$39 USD
In Stock

Melanotan II 10mg

Batch purity 99.3%
$32 USD
In Stock

MOTS-C 10mg

Batch purity 99.4%
$32 USD
In Stock

Retatrutide 10mg

Batch purity 99.7%· 20mg lot
$63 USD
In Stock

Retatrutide 20mg

Batch purity 99.7%
$97 USD
In Stock

Semaglutide 10mg

$49 USD

Your Cart

Your cart is empty

Browse our catalog to add research compounds.